H. Lundbeck A/s

Novo Nordisk Healthcare Ag

Haleh Ahmadian

Hans Petersen

Michael Harold Rock

Robert Dancer

Yasuyoshi Ueda

Takashi Yoshida

Toshihiro Takeda

Arne Staby

Janus Krarup

Takahisa Kato

Susanne Bang

Thomas Budde Hansen

Lars Ole Lyngso

Are Bogsnes

Daniel E Rasmussen

Shogo Yamamoto

Anne Charlotte Arentsen

Naoki Taoka

The present invention relates to Vitamin K-dependent protein compositions having a very low, or negligible, content of protein contaminants. The present invention also relates to method applicable in the preparation of such Vitamin K-dependent protein compositions. Such methods may either be used alone or in sequential combination with the purpose of reducing the relative content of protein contaminants. The present invention is particularly relevant in the preparation of compositions of coagulation factors selected from Factor X polypeptides (FX/FXa), Factor IX polypeptides (FIX/FIXa), Factor VII polypeptides (FVII/FVIIa), and the anticoagulant Protein C, in particular Factor VII polypeptides.

Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest

The present invention relates to a novel method for the preparation of diol intermediates having the formula (II) and/or the opposite enantiomer of an acylated diol having the formula (IV) useful for the preparation of escitalopram involving selective enzymatic acylation or deacylation. 

Method for the separation of intermediates which may be used for the preparation of escitalopram

Methods for manufacture of citalopram through stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans are disclosed.

Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans

Method for the preparation of citalopram

Growing community of inventors

Solrød Strand, Denmark

Haleh Ahmadian